Article
CYP2D6 Genotypes Do Not Affect Clozapine Levels in a Large, Multicenter Cohort: Time Has Come to Revise Food and Drug Administration's Clozapine Packet Insert.
Schizophrenia bulletin - 3 Jul 2026
Schoretsanitis Georgios, Laaboub Nermine, Crettol Séverine, Lenk Hasan Çağın, Bråten Line Skute, Ranjbar Setareh, Piras Marianna, Dubath Céline, Grandjean Carole, Vandenberghe Frederik, Ansermot Nicolas, Gamma Franziska, Plessen Kerstin Jessica, von Gunten Armin, Conus Philippe, Eap Chin Bin, Molden Espen
Abstract excerpt
BACKGROUND AND HYPOTHESIS: The US Food and Drug Administration (FDA) package insert for clozapine states that cytochrome P450 (CYP) 2D6 is important in clozapine metabolism, implying that CYP2D6 genotypes should be considered in clozapine dosing. We investigated differences for clozapine concentration-to-dose (C/D) ratios, as a pharmacokinetic measure, in relation to CYP2D6 phenotype. STUDY DESIGN: Linear...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.